Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Top 50 Companies 2018: Notes & Methodology

For this 32nd annual special report, Med Ad News editors rank and profile the world’s top 50 companies that generate revenue from healthcare products.

Read More »

2018 Annual Report: Top 50 Companies – Looking to future challenges

The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.

Read More »

AbbVie 2018: Still Humira

While other products are showing signs of growth, the fate of AbbVie is still in the hands of the iconic autoimmune drug.

Read More »

Amgen 2018: Company-wide transformation

From 2014 through year-end 2017, Amgen delivered $1.5 billion in transformation and process improvement savings that the company has reinvested in launching new medicines, advancing the product pipeline, and pursuing external business development opportunities.

Read More »

AstraZeneca 2018: Gaining strength

Even as AstraZeneca’s top-selling drugs continued to be affected by generic competition in 2017, executives say the company’s growth platforms will return the business to growth in 2018 and beyond.

Read More »

Bayer 2018: Acquisition achieved

With U.S. antitrust approval of Bayer’s acquisition of Monsanto, the company is looking ahead.

Read More »

Bristol-Myers Squibb 2018: The future is now

With two potential $6 billion brands now at the top of the company’s portfolio, Bristol-Myers Squibb is officially through the lean times.

Read More »

Gilead 2018: The party’s over

On the far side of the company’s brief but transformative adventure with Sovaldi and Harvoni, Gilead is returning to earth with a solid portfolio of HIV drugs.

Read More »

GlaxoSmithKline 2018: GSK’s next growth wave

GlaxoSmithKline management has embarked on the start of a new approach to R&D that aims to capitalize on the company’s assets within a promising early-stage pipeline.

Read More »

Company of the Year 2018 — Johnson & Johnson: Defining the future of healthcare

The executive management team of this “132-year-old startup” company is excited about a future that lies beyond the intersection of science and technology.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom